HuB Inhibitors
HuB inhibitors belong to a distinct chemical class of compounds that have garnered significant attention in the field of molecular biology. These inhibitors are designed to target a specific protein known as HuB (also called ELAVL1 or HuR), which plays a pivotal role in post-transcriptional regulation of gene expression. HuB belongs to a family of RNA-binding proteins called ELAVL (Embryonic Lethal Abnormal Vision in Drosophila), and it is characterized by its ability to bind to mRNA molecules, thereby influencing their stability, localization, and translation. By specifically targeting HuB, these inhibitors aim to modulate its function, ultimately regulating the expression of target genes.
The development of HuB inhibitors is grounded in the growing understanding of HuB's importance in various cellular processes, including cell proliferation, apoptosis, and immune response. Researchers have sought to design small molecules or peptides that can disrupt the interactions between HuB and its mRNA targets, thereby altering the fate of these mRNA molecules within the cell. Such inhibitors are typically designed with a high degree of specificity to minimize off-target effects and to ensure that they selectively interact with HuB. The study and utilization of HuB inhibitors hold the potential to provide valuable insights into the mechanisms of post-transcriptional gene regulation and may offer new avenues for research in fields such as cancer biology, immunology, and neurobiology, where HuB-mediated mRNA regulation plays a crucial role in normal and pathological cellular processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Suppresses abnormal cell proliferation in cancer. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division in cancer and autoimmune diseases. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Selective estrogen receptor modulator (SERM). | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for non-small cell lung cancer, inhibiting tumor cell proliferation. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Androgen receptor antagonist for prostate cancer, disrupting androgen signaling and inhibiting tumor growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multikinase inhibitor targeting Raf kinases, VEGFR, and PDGFR, leading to reduced tumor angiogenesis and growth in various cancers. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor blocking protein degradation, used for multiple myeloma and certain lymphomas, inducing cell death in cancer cells. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
mTOR inhibitor disrupting cell cycle progression and angiogenesis, employed in various cancers, including renal cell carcinoma. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dual BCR-ABL and Src family kinase inhibitor. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Bruton's tyrosine kinase (BTK) inhibitor used in B cell malignancies, blocking B cell signaling pathways and inhibiting cancer growth. | ||||||